Trial Profile
Prospective study for the usefulness of single nucleotide polymorphism of immune related genes as a predictive factor of nivolumab effect for the patients with advanced non-small cell lung cancer
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 22 Jul 2019
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacogenomic; Therapeutic Use
- 18 Jul 2019 Planned initiation date changed from 1 Aug 2018 to 1 Aug 2019.
- 19 Jul 2018 New trial record